BRMS1L Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma cell line, featuring targeted disruption of the BRMS1L gene. This loss-of-function model enables investigation of BRMS1L??s role as a metastasis suppressor, particularly its function in inhibiting epithelial-mesenchymal transition (EMT) and cell migration. The polyclonal format provides a heterogeneous pool of edited cells, suitable for population-based assays without clonal selection artifacts.
The A-549 cell line, established from a lung carcinoma of a 58-year-old male, is a widely used model for human lung adenocarcinoma and respiratory epithelium. It retains key oncogenic features such as KRAS activation and aberrant TGF-?? signaling, making it pertinent for studying EMT and metastatic progression. In this context, loss of BRMS1L is expected to unmask pro-metastatic programs, enhancing the model??s relevance for translational research.
Mechanistically, BRMS1L is a core component of the SIN3A-HDAC1/2 transcriptional repressor complex that deacetylates histones to silence pro-metastatic genes like SNAI1 and TWIST1. This repression inhibits EMT, reduces matrix metalloproteinase expression (MMP2, MMP9), and restores epithelial marker CDH1. BRMS1L activity is regulated downstream of TGF-??1/SMAD2/3 signaling and transcription factors such as EGR1, and it interacts with metastasis suppressor BRMS1 and retinoblastoma protein RB1, linking transcriptional repression to cell cycle control.
In A-549 cells, BRMS1L knockout is anticipated to exacerbate EMT and migration, mirroring aggressive metastatic phenotypes. The interplay between TGF-??/SMAD-driven EMT and WNT signaling can be examined in this isogenic background, providing insights into how loss of a metastasis suppressor cooperates with oncogenic drivers. This model is valuable for studying the transition from localized carcinoma to invasive disease.
Applications include profiling HDAC inhibitor responses, validating drug targets in the SIN3-HDAC axis, and performing functional assays such as transwell migration, wound healing, and colony formation. Changes in EMT markers (SNAI1, TWIST1, CDH1) can be monitored by RT-qPCR and Western blotting. For further information, please contact Ascent Research.
